- Zacks•7 days ago
Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.
- Zacks•11 days ago
Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.
- American City Business Journals•11 days ago
Foundation Medicine has appointed a top Genentech commercial executive as its new CEO, the Cambridge cancer diagnostic firm announced Friday. Troy Cox, who previously led Genentech’s oncology portfolio, will take over as CEO of Foundation (FMI) beginning Feb. 6. The company said that its current CEO, Michael Pellini, who has served in that role since 2011, would become chairman of its board of directors on that date.
RHHVF : Summary for ROCHE HLDGS AG GENUSSCHEINE NPV - Yahoo Finance
Roche Holding AG (RHHVF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.80|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|